The U.S. Food and Drug Administration (FDA) granted initial approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) on December 27, 2024. This approval designates the product as a new dosage form, expanding the available formulations of nivolumab.
Background
Opdivo Qvantig is a combination product developed by Bristol-Myers Squibb. It consists of nivolumab, an established therapeutic agent, and hyaluronidase-nvhy. The FDA's initial approval on December 27, 2024, specifically classifies Opdivo Qvantig as a Type 3 - New Dosage Form. This classification indicates that while the active ingredient nivolumab may be known, this particular formulation represents a distinct and newly approved method of delivery.
What this means
The initial FDA approval of Opdivo Qvantig as a new dosage form provides clinicians with an additional option for administering nivolumab. New dosage forms, such as those incorporating hyaluronidase-nvhy, are often developed to offer benefits like subcutaneous administration, which can potentially reduce treatment time and improve patient convenience compared to intravenous infusions. While the specific advantages of this particular new dosage form are not detailed in the approval information, its availability expands the therapeutic landscape for patients who may benefit from nivolumab, offering flexibility in treatment delivery. This development allows healthcare providers to consider Opdivo Qvantig as an alternative formulation within the existing treatment paradigms where nivolumab is indicated.
Source
The information regarding this initial FDA approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Opdivo Qvantig (BLA 761381) was granted on December 27, 2024, and is publicly accessible via accessdata.fda.gov. The official record identifies Bristol-Myers Squibb as the sponsor and categorizes the approval as a Type 3 - New Dosage Form.